Press Releases

-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein- -Approximately 800 more people with CF in the US are

- For the primary endpoint, patients treated with povetacicept achieved a 52.0% reduction from baseline in proteinuria as measured by 24-hour urine protein to creatinine ratio (UPCR) and achieved a statistically significant and clinically meaningful 49.8% reduction in UPCR versus placebo (P<

BOSTON --(BUSINESS WIRE)--Mar. 5, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Charlie Wagner, Chief Operating and Financial Officer, and Duncan McKechnie, Chief Commercial Officer, will participate in a

-Over 90% of patients in the study were opioid free through the end of multimodal treatment with JOURNAVX- -These data have been accepted for oral presentation at the American Academy of Pain Medicine Meeting - BOSTON --(BUSINESS WIRE)--Mar. 5, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq:

BOSTON --(BUSINESS WIRE)--Feb. 17, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in TD Cowen’s 46 th Annual Health Care Conference. Reshma Kewalramani, President and Chief Executive Officer will participate in a fireside chat on Tuesday, March 3,

— Full year total revenue of $12.0 billion, a 9% increase compared to full year 2024; fourth quarter total revenue of $3.19 billion, a 10% increase compared to fourth quarter 2024 — — Company provides full year 2026 total revenue guidance of $12.95 billion to $13.1 billion, with non-CF products

BOSTON --(BUSINESS WIRE)--Jan. 20, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026 , after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .

BOSTON --(BUSINESS WIRE)--Jan. 11, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced business and program updates ahead of upcoming investor meetings in January, including the company’s scheduled webcast from the 44th annual J.P.

BOSTON --(BUSINESS WIRE)--Dec. 22, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani , Chief Executive Officer and President, will present at the 44 th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 , at 5:15 p.m.

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients - - Efficacy and safety data in children 5-11 years are consistent with the

BOSTON --(BUSINESS WIRE)--Nov. 19, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in Citi’s 2025 Global Healthcare Conference. Charlie Wagner , Chief Operating and Financial Officer, and David Altshuler , Chief Scientific Officer, will participate

- 48-week data show a 64% decrease from baseline in proteinuria in IgA nephropathy, 82% decrease from baseline in proteinuria in primary membranous nephropathy, and stabilization of estimated glomerular filtration rate across both diseases - - Vertex on track to initiate rolling submission of

— Total revenue of $3.08 billion , an 11% increase compared to Q3 2024 — — Refined full year financial guidance: total revenue guidance now $11.9 to $12.0 billion and total   combined non-GAAP R&D, AIPR&D, and SG&A expense guidance now $5.0 to $5.1 billion — — R&D pipeline continues to make

BOSTON --(BUSINESS WIRE)--Oct. 27, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the UBS Global Healthcare Conference . Reshma Kewalramani , President and Chief Executive Officer will participate in a fireside chat on Tuesday, November 11,

- Data presented on outcomes following treatment with CFTR modulators add to growing body of evidence that reduced level of sweat chloride is associated with improved clinical outcomes, particularly in younger people with cystic fibrosis - BOSTON --(BUSINESS WIRE)--Oct.

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous

BOSTON --(BUSINESS WIRE)--Oct. 6, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2025 financial results on Monday, November 3, 2025 , after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .

- Food and Drug Administration granted Breakthrough Therapy Designation for povetacicept in IgA nephropathy; on track to file for accelerated approval in the U.S. in H1 2026 if 36-week interim analysis data positive - - Enrollment completed for interim analysis cohort of AMPLITUDE global Phase 2/3

- Tatum shares, for the first time, his treatment experience with JOURNAVX while recovering from Achilles injury - BOSTON --(BUSINESS WIRE)--Sep. 23, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)   today announced that the company has partnered with basketball world champion Jayson

- CASGEVY is the first, and only, gene editing therapy approved for the treatment of transfusion-dependent beta thalassemia ( TDT) and sickle cell disease (SCD) in Europe - - Italy has the largest population of people living with TDT in Europe   - LONDON --(BUSINESS WIRE)--Sep.